Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).

The present invention is a liquid composition containing (A) an isoxazolium salt and water, the composition being acidic.

The present invention is a liquid composition containing (A) an isoxazolium salt and water, the composition being acidic.

The present disclosure relates to a pharmaceutical composition containing a cinnamic amide derivative that activates FXR or an isomer, solvate, or pharmaceutically acceptable salt thereof, and a method for preparing the same.